EDG-7500
Targeting HCM and other serious diseases of cardiac diastolic dysfunction
We are developing EDG-7500, a selective cardiac sarcomere modulator, with the aim to slow early contraction velocity and address impaired cardiac relaxation associated with hypertrophic cardiomyopathy (HCM).
Hypertrophic Cardiomyopathy
Two major forms of HCM include obstructive (oHCM) and non-obstructive (nHCM), each leading to impaired cardiac performance. In oHCM, as the left ventricle (LV) contracts (systole) to eject oxygenated blood from the heart into systemic circulation, the mitral valve makes physical contact with the hypertrophied septal wall. This contact underlies the basis of the obstructed ejection of blood through the LV outflow tract (LVOT) creating a pressure difference, or gradient (LVOT-G) between the LV cavity and systemic circulation. In nHCM, the hypertrophy is more symmetrically distributed in the LV walls, therefore the patient does not develop LVOT obstruction nor pressure gradient. However due to LV hypertrophy and stiffness, LV relaxation is impaired and LV filling with blood (diastole) is significantly reduced.
Abnormalities in a HCM Heart Lead to Impaired Cardiac Performance
HCM is a Disease of the Sarcomere
In HCM, the disease causes an increase in acto-myosin head engagement, making the heart hyperdynamic and relaxation impaired.
Normal contraction
Healthy sarcomere
Excessive contraction
and impaired relaxation
In HCM, too many ‘motors’ engaged during systole and diastole
About EDG-7500
Targeting the sarcomere
EDG-7500 is a novel oral, selective cardiac sarcomere modulator for the treatment of HCM and other serious diseases of cardiac diastolic dysfunction.
Potential to address both obstructive and non-obstructive HCM
In preclinical data in models of both obstructive and non-obstructive HCM, EDG-7500 has been shown to improve cardiac relaxation and filling, without significant impairment of systolic performance.
Designed to address unmet needs in HCM
Preclinical data support EDG-7500 has the potential for significant efficacy, measured by gradient response, without sacrificing safety concerns, measured in minimal changes in ejection fraction. EDG-7500 is currently in clinical trials in oHCM and nHCM.
EDG-7500 is an investigational therapy that has not been approved for use in hypertrophic cardiomyopathy by any regulatory agency, as its safety and effectiveness have not been established for the treatment of this disease.
